Development of interferon cancer gene therapy by optimizing structure/pharmacokinetics/activity of transgene product
| Project/Area Number |
25713003
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (A)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Research Field |
Physical pharmacy
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
Takahashi Yuki 京都大学, 薬学研究科(研究院), 助教 (00547870)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥24,050,000 (Direct Cost: ¥18,500,000、Indirect Cost: ¥5,550,000)
Fiscal Year 2015: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2014: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2013: ¥12,220,000 (Direct Cost: ¥9,400,000、Indirect Cost: ¥2,820,000)
|
|---|
| Keywords | インターフェロン / 遺伝子治療 / DDS / ルシフェラーゼ |
|---|
| Outline of Final Research Achievements |
In the present study, we designed IFNγ derivatives fused with a fibrin-binding pentapeptide (CREKA) for the development of effective IFNγ cancer gene therapy. We constructed plasmid DNA (pDNA) expressing an IFNγ-CREKA fusion protein and administered the pDNA into tumor-bearing mice by hydrodynamic injection. The fusion protein was detected to bind to fibrin clots in the tumor tissue. Moreover, tumor growth was suppressed by the administration of the pDNA. In conclusion, it was shown that IFNγ-CREKA fusion protein can be used to improve therapeutic effect of IFNγ cancer gene therapy.
|
Report
(4 results)
Research Products
(4 results)
